絞り込み

16525

広告

Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017.

著者 Magnes T , Egle A , Greil R , Melchardt T
Memo.2017 ; 10(4):220-223.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (40view , 0users)

Full Text Sources

Miscellaneous

At the annual ASCO meeting clinically relevant data concerning the management of advanced head and neck cancer that will influence clinical practice in the future were presented. Chemoradiation with high-dose cisplatin remains the mainstay of treatment for patients with locally advanced squamous cell head and neck cancer. Adjuvant therapy with afatinib following chemoradiation failed to show clinical benefit. The combination of bevacizumab with platinum-based chemotherapy improved progression-free survival but did not lead to a significant difference in overall survival compared to chemotherapy alone. However, the addition of immunotherapy may improve multimodal treatment concepts in locally advanced disease and new treatment combinations might overcome resistance to checkpoint inhibition.
PMID: 29250200 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード